Yuviwel FDA Approval: Once‑Weekly CNP for Achondroplasia
Overview Yuviwel (navepegritide) is a once‑weekly, subcutaneous C‑type natriuretic peptide (CNP) analog approved by the U.S. Food and Drug Administration in February 2026 to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses.[1,2]…